Drug
Nadofaragene Firadenovec
Drug Profile
| Therapeutic Class | Gene Therapy |
| Drug Class | Gene Therapy |
| Group | Gene Therapy |
| Mechanism of Action | Adenoviral vector delivering IFNα2b gene |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Construct-dependent, often intentionally radiation-enhancing (suicide gene/prodrug, RT-inducible promoters, immune-gene delivery) (Advani et al. Journal of Clinical Oncology 2007; Vlachaki et al. International Journal of Radiation Oncology, Biology, Physics 2001; Marco et al. Cancer Cell 2026). Adverse events likewise depends on the construct—tumor-targeted/RT-inducible expression aims to spare normal tissue, whereas immune-gene approaches carry a theoretical local/systemic inflammatory adverse event risk.
Data on this page refer exclusively to patients treated with
Nadofaragene Firadenovec combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Gene Therapy group page.